How much evantumumab should be used per month? Does the dose need to be adjusted based on the patient's condition?

Amivantamab (amivantamab) is a bispecific antibody targeting EGFR and MET, mainly used to treat patients with EGFR Patients with non-small cell lung cancer (NSCLC) with exon 20 insertion mutations. The drug inhibits the growth of tumor cells and promotes their apoptosis by blocking the EGFR and MET signaling pathways. Due to its specific mechanism of action, the dose of evantumumab is usually calculated based on the patient's weight to ensure efficacy while reducing the risk of side effects.

In terms of dosage, the recommended dose of evantumumab is generally 1,050 mg per dose for patients weighing less than 80kg, and 1,400mg per dose for patients weighing more than 80kg. The first month of treatment usually requires one infusion in the first and second weeks, and then every two weeks. The specific dosage and infusion frequency should be adjusted by the doctor according to the patient's specific conditions to ensure the best therapeutic effect.

The dose of evantumumab may be adjusted based on the patient's condition. For example, if a patient experiences serious adverse reactions during treatment, such as infusion reactions, skin toxicity, or liver function abnormalities, doctors may appropriately reduce the dose or adjust the infusion interval. In some cases, treatment may need to be suspended or discontinued if side effects are severe and intolerable. Therefore, when using evantumumab, patients should closely monitor their own reactions and communicate with their doctors in a timely manner to obtain the best treatment plan.

Evantumumab has just been launched in China. Due to its short time on the market, it may be difficult for domestic patients to purchase the drug directly. Therefore, some patients may consider overseas versions, such as the original version already available in Hong Kong, China. It is understood that the price of this version is about 10,000 yuan, which is relatively controllable compared to other imported anti-cancer drugs. For patients whose financial conditions permit, they may consider obtaining the drug through formal channels to ensure the continuity and safety of treatment.

Reference materials:https://www.rybrevant.com/